Proxima 4 Commercialisation Strategy Update

Sphere Medical Holding plc

Proxima 4 Commercialisation Strategy Update

Cambridge, UK, 17 August 2015: Sphere Medical Holding plc (AIM: SPHR.L), ("Sphere Medical" or the "Company") a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announced today that it has retained all commercialisation rights to Proxima 4 and is free to enter into discussions with other interested partners, following a decision by Ortho Clinical Diagnostics not to exercise its option to enter into negotiations to acquire exclusive global commercialisation rights for Proxima 4. Sphere Medical entered into the collaboration agreement with Ortho Clinical Diagnostics, a manufacturer of in vitro diagnostic products, in 2013 for the development of Proxima 4. In 2014, Ortho Clinical Diagnostics was purchased by The Carlyle Group.

The Company will continue with the finalisation of the submission process for the CE-marking for the Proxima 4 device whilst it further develops strategies for commercialisation. Proxima 4 will be Sphere Medical's second commercial iteration of the system, incorporating glucose and sodium analysis within the sensor panel and adding connectivity to hospital information systems.

Dr. Wolfgang Rencken, Chief Executive Officer of Sphere, said: "Whilst Ortho Clinical Diagnostics focusses on its core business and has chosen not to pursue distribution of Proxima 4, Sphere is now free to explore commercial agreements with other interested parties. We look forward to engaging with parties who are well placed to sell into the attractive, global critical care market."

For further information, please contact:

Notes for Editors

About Sphere Medical (AIM: SPHR.L)

Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.

The Company's strategy is focused on developing the Proxima (CE-marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already marketing its Proxima product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK, Germany, the Netherlands and Belgium. The Company also proposes to work with partners for the worldwide distribution of Proxima.

Proxima delivers near real time analysis of blood gases, electrolytes and metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.

For further information, please visit www.spheremedical.com